Loading
aTYR PHARMA Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by SCHIMMEL PAUL, was filed 09 Oct 2025.
aTYR PHARMA Inc: what insiders have been doing
aTYR PHARMA Inc, classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). Over the twelve months to 19 October 2026, 3 filings were filed, from 3 insiders.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
No insider has bought aTYR PHARMA Inc shares on the open market in the past twelve months. The median gap between a trade and its publication by SEC (Form 4) is 1 day. The legal deadline for a Form 4 is two business days after the transaction.
For context, the typical company on the same exchange (median of 5,458 companies) published 22 filings over the same period, against 3 filings here. The full history, which starts in 2016, counts 19 purchases against 1 sale.
In the same sector, recent insider purchases at Vivos Inc and Anixa Biosciences Inc also feature in our signals. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
40
Thresholds
n/a
Buy Volume
€3M
19 ops. · all time
Sell Volume
€8,875
1 ops. · all time
Who traded when
BuySaleJane A. Gross1 buy
Paul Schimmel1 buy
Since the insiders bought
- -31.6%Entry US$1.06 · Close at T+90 US$0.73
- -78.9%Entry US$3.87 · Close at T+365 US$0.81
- +175.3%Entry US$1.98 · Close at T+365 US$5.45
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate aTYR PHARMA Inc Buy (bullish), based on 7 analysts. Average price target: US$2.86.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.55
Analyst consensus
7 analystsBuy
US$1.00Target US$2.86(+417%)US$7.00
Income statement
RevenueUS$190k
EBITDA-US$76.1M-40039% margin
Net income-US$74.1M-39009.5% margin
Valuation
PER (forward)-1.2x
P/Book1.1x
Beta0.52
Balance sheet & cash
Market capUS$54.2M
Total debtUS$12M
Free Cash Flow-US$62.1M
Debt / Equity23%
Profitability & ownership
ROE-98.7%
ROA-46.6%
% insiders2.5%
% institutions40.2%
Last declaration on 4 February 2026
Declarations40 total
2,687 sharesCommon StockSEC:0001193125-26-037996:0
10,375 sharesCommon StockSEC:0001193125-26-038007:0
3,750 sharesCommon StockSEC:0001193125-26-038002:0
682,001 shares@ US$0.898100.0% of flowCommon StockSEC:0001193125-25-236131:0
Canonical exit: 6 Jan 2026 (T+90)
3,750 shares@ US$4.00100.0% of flowCommon StockSEC:0000950170-25-040600:0
Canonical exit: 15 Jun 2025 (T+90)
10,375 sharesCommon StockSEC:0000950170-25-013891:0
3,750 sharesCommon StockSEC:0000950170-25-013884:0
2,687 sharesCommon StockSEC:0000950170-25-013878:0
41,052 shares@ US$1.74172.8% of flowCommon StockSEC:0000950170-24-086159:0
Canonical exit: 20 Oct 2024 (T+90)
5,000 shares@ US$1.8552100.0% of flowCommon StockSEC:0000950170-24-069680:0
Canonical exit: 3 Sept 2024 (T+90)
5,000 shares@ US$1.7942.1% of flowCommon StockSEC:0000950170-24-067668:0
Canonical exit: 29 Aug 2024 (T+90)
20,000 shares@ US$1.80716.0% of flowCommon StockSEC:0000950170-24-067666:0
Canonical exit: 29 Aug 2024 (T+90)
50,000 shares@ US$1.75100.0% of flowCommon StockSEC:0000950170-24-067989:0
Canonical exit: 28 Aug 2024 (T+90)
2,688 sharesCommon stockSEC:0001209191-24-002945:0
10,375 sharesCommon stockSEC:0001209191-24-002949:0
3,750 sharesCommon stockSEC:0001209191-24-002947:0
3,000 shares@ US$1.171.6% of flowCommon StockSEC:0001209191-23-058377:0
Canonical exit: 10 Mar 2024 (T+90)
1,422 shares@ US$1.1380.7% of flowCommon StockSEC:0001209191-23-054976:0
Canonical exit: 8 Feb 2024 (T+90)
15,000 shares@ US$2.014913.2% of flowCommon StockSEC:0001209191-23-043943:0
Canonical exit: 26 Oct 2023 (T+90)
6,000 shares0Common StockSEC:0001209191-23-031008:0
200,000 shares@ US$2.2517.5% of flowCommon StockSEC:0001209191-23-028607:0
Canonical exit: 8 Aug 2023 (T+90)
6,000 sharesCommon StockSEC:0001209191-23-026069:0
6,000 sharesCommon stockSEC:0001209191-23-026065:0
6,000 sharesCommon stockSEC:0001209191-23-026070:0
6,000 sharesCommon stockSEC:0001209191-23-026067:0
25 of 40 declarations
About aTYR PHARMA Inc
aTyr Pharma, Inc. (Nasdaq: ATYR) is a United States-based clinical-stage biotechnology company headquartered in San Diego, California, and listed on the NASDAQ market in the United States. For investors, it represents a specialized small-cap biotech story built around a proprietary discovery platform focused on aminoacyl-tRNA synthetase biology. The company is developing first-in-class therapies for fibrosis and inflammation, with a profile that is still pre-commercial and therefore highly dependent on clinical execution, regulatory feedback, and funding discipline.
Founded by professors including Paul Schimmel, aTyr was built on a distinctive scientific thesis: that tRNA synthetases can be translated into therapeutic modalities with disease-modifying potential. Its lead candidate is efzofitimod, a tRNA synthetase-derived therapeutic designed to selectively modulate activated myeloid cells through neuropilin-2, with the goal of resolving inflammation without broad immune suppression and potentially limiting fibrotic progression. aTyr is currently evaluating efzofitimod in pulmonary sarcoidosis, a major form of interstitial lung disease (ILD), and in systemic sclerosis-related ILD (SSc-ILD). The company also has earlier-stage assets such as ATYR0101, which remain part of the broader platform strategy.
Read moreShow less
From a competitive standpoint, aTyr operates in a niche but strategically attractive segment of biotech: pulmonary inflammatory and fibrotic disorders. It does not compete head-on with large diversified pharmaceutical companies on scale, but rather with other development-stage peers pursuing targeted approaches in rare and hard-to-treat diseases. Its differentiators are scientific novelty, orphan-disease focus, and a platform intended to generate potentially differentiated medicines. Efzofitimod has received orphan drug designations in the United States, Europe, and Japan, which may enhance development and market-exclusivity prospects if the program advances successfully.
Recent developments are central to the investment case. In 2025, aTyr reported Phase 3 EFZO-FIT results in pulmonary sarcoidosis. The study did not meet its primary endpoint, but the company highlighted favorable signals across several pre-specified secondary measures and a safety profile consistent with prior trials. Management subsequently indicated that it expects to meet with the FDA in April 2026 to discuss the data and determine the next steps for efzofitimod. In parallel, the Phase 2 EFZO-CONNECT study in SSc-ILD remains on track to complete enrollment in the first half of 2026. The company also ended 2025 with a meaningful cash position for a biotech of its stage, supporting near-term operating flexibility. For shareholders, aTyr remains a high-risk, catalyst-driven NASDAQ-listed biotech in the United States, with value heavily tied to clinical readouts, FDA dialogue, and the eventual commercial viability of its lead program.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
